Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin

Open access

Abstract

The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further challenged by drug-drug interactions, toxicity, and constraints in administration routes. Despite the need for more antifungal drug options, no new classes of antifungal drugs have become available over the last 2 decades, and only one single new agent from a known antifungal class has been approved in the last decade. Nevertheless, there is hope on the horizon, with a number of new antifungal classes in late-stage clinical development. In this review, we describe the mechanisms of drug resistance employed by fungi and extensively discuss the most promising drugs in development, including fosmanogepix (a novel Gwt1 enzyme inhibitor), ibrexafungerp (a first-in-class triterpenoid), olorofim (a novel dihyroorotate dehydrogenase enzyme inhibitor), opelconazole (a novel triazole optimized for inhalation), and rezafungin (an echinocandin designed to be dosed once weekly). We focus on the mechanism of action and pharmacokinetics, as well as the spectrum of activity and stages of clinical development. We also highlight the potential future role of these drugs and unmet needs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40265-021-01611-0

Cites

190 of 190 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mechanism of action of novel antifungal drugs discussed in this review. DHODH dihydroorotate dehydrogenase
Fig. 1 Mechanism of action of novel antifungal drugs discussed in this review. DHODH dihydroorotate dehydrogenaseCC BY-NC · PubMed Central
Fig. 2 Activity of the new antifungal drugs in the pipeline against most common fungal pathogens
Fig. 2 Activity of the new antifungal drugs in the pipeline against most common fungal pathogensCC BY-NC · PubMed Central
Fig. 3 Timetable of clinical trials evaluating fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. IV intravenous
Fig. 3 Timetable of clinical trials evaluating fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. IV intravenousCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 188 references

Research works printed but not linked: 9

  1. Vale-Silva L, Ischer F, Leibundgut-Landmann S, Sanglard D. Gain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells. Infect Immun. 2013;81(5):1709–20. · DOI · Paper page
  2. Hagiwara D, Miura D, Shimizu K, Paul S, Ohba A, Gonoi T, et al. A novel Zn2-Cys6 transcription factor AtrR plays a key role in an azole resistance mechanism of Aspergillus fumigatus by co-regulating cyp51A and cdr1B expressions. PLoS Pathog. 2017;13(1):e1006096. · DOI · Paper page
  3. Ghannoum M, Long L, Larkin EL, Isham N, Sherif R, Borroto-Esoda K, et al. SCY-078, a novel oral glucan synthase inhibitor, for the treatment of invasive aspergillosis: evaluation of antifungal activity singly and in combination. Antimicrob Agents Chemother. 2018;62(6):e00244-18. · DOI · Paper page
  4. Trucksis M, Garrett G, Heriman I. A phase I multiple rising dose study evaluating safety, tolerability, and pharmacokinetics of MK-3118, oral glucan synthase inhibitor, in healthy volunteers. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011; Chicago (IL).
  5. Kennedy T AG, Steiner J, Heep M, Oliver J, Sibley G, Law D., editor Multiple dose pharmacokinetics of an immediate-release tablet formulation of F901318 in healthy male and female subjects. In: Proceedings of the 27th European congress of clinical microbiology and infectious diseases; 22–25 April 2017; Vienna.
  6. Kennedy TAG, Steiner J, Heep M, Oliver J, Sibley G, Law D, editor Assessment of the duraiton of infusion on the tolerability and repaet dose pharmacokinetics of F901318 in health-volunteers (abstract P1711). In: Proceedings of the 27th European congress of clinical microbiology and infectious diseases; 22-25 April 2017; Vienna.
  7. Tio SH TK, Ng G, Rex JH, Carney D, Slavin M. Olorofim for a case of severe disseminated Lomentospora prolificans infection. In: Proceedings of the 30th European Congress of Clinical Microbiology and Infectious Diseases; 18–21 April 2020; Paris.
  8. Chen S RN, Cunneen S, Cornelissen K, Rex JH, Heath CH, Harvey E. A case of Lomentospora prolificans treated with the novel antifungal olorofim. In: Proceedings of the 30th European Congress of Clinical Microbiology and Infectious Diseases; 18–21 April 2020; Paris.
  9. Harvey EFL, Rex JH, Thompson G. Successful use of the novel antifungal olorofim in the treatment of dissemianted coccidioidomycosis. Proceedings of the 30th European Congress of Clinical Microbiology and Infectious Diseases; 18-21 April 2020; Paris.

Cited by

See all 487

Metadata

Authors
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., Wiederhold, N., & Jenks, J. D.
Affiliations
  • Medical University of Graz (AT)
  • University of Cologne (DE)
  • Hackensack Meridian Health (US)
  • Washington University in St. Louis (US)
  • University of California Davis Medical Center (US)
  • The University of Texas at San Antonio Health Science Center (US)
  • University of California San Diego (US)
Corresponding author
Hoenigl, Martin
Venue
Drugs
Published
2021-10
Volume
81
Issue
15
Pages
1703-1729
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W3202074216
Cited by
467
References
188
Citations by year
2026: 78 · 2025: 116 · 2024: 117 · 2023: 98 · 2022: 54 · 2021: 3
FWCI
7.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • national institute of allergy and infectious diseases (UL1TR001442)
  • Medical University of Graz
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords
antifungal drug development, fosmanogepix, ibrexafungerp, olorofim, rezafungin, invasive fungal infections, antifungal resistance mechanisms, triterpenoids, triazoles, echinocandins, pharmacokinetics, drug-drug interactions, unmet medical needs
MeSH terms
Invasive Fungal Infections, Drug Development, Animals, Antifungal Agents, Drug Interactions, Fungi, Humans, Drug Resistance, Fungal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. https://app.cochat.ai/papers/10.1007/s40265-021-01611-0
The paper
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., Wiederhold, N., & Jenks, J. D. (2021). The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. https://doi.org/10.1007/s40265-021-01611-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.